MUTATIONS WITHIN THE RNASE-H DOMAIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE ABOLISH VIRUS INFECTIVITY

被引:134
作者
TISDALE, M [1 ]
SCHULZE, T [1 ]
LARDER, BA [1 ]
MOELLING, K [1 ]
机构
[1] MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,W-1000 BERLIN 33,GERMANY
关键词
D O I
10.1099/0022-1317-72-1-59
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The C-terminal region of human immunodeficiency virus (HIV) reverse transcriptase (RT) contains the domain responsible for RNase H activity. To determine the importance of this RNase H domain, specific changes in the C-terminal region of a recombinant RT expressed in Escherichia coli were introduced by amino acid substitutions and specific deletions. The enzyme activities of purified wild-type and mutant RT/RNase H proteins, standardized for protein content, were compared by filter assays and thermal inactivation kinetics. A point mutation of His 539-->Asn produced an enzyme with a marked thermolabile RNase H function (nine-fold increase in inactivation), whereas RT function was only marginally more labile than that of the wild-type (two-fold). A second mutation, His 539-->Asp, impaired both enzyme activities to a similar degree (four-to five-fold). A C-terminal deletion of 19 amino acids (aa) (aa 540 to 558) and a C-terminal truncation of 21 aa (aa 540 to 560) reduced RT as well as RNase H activity. A 130 aa deletion enzyme exhibited no RNase H activity and insufficient RT activity to allow inactivation studies. Two mutants, the 19 aa deletion and His-->Asn, were introduced into proviral HIV-1 DNA clones to determine whether changes in enzyme activity, particularly RNase H activity, affected virus infectivity. Both mutants were non-infectious, indicating that the C-terminal 19 to 21 amino acids and His 539 of the RT/RNase H protein are essential for HIV replication. These results are consistent with the assumption that RNase H is essential for the infectivity of HIV-1.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 33 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]   GENETIC-RECOMBINATION OF HUMAN IMMUNODEFICIENCY VIRUS [J].
CLAVEL, F ;
HOGGAN, MD ;
WILLEY, RL ;
STREBEL, K ;
MARTIN, MA ;
REPASKE, R .
JOURNAL OF VIROLOGY, 1989, 63 (03) :1455-1459
[3]   A MOLECULAR CLONE OF HTLV-III WITH BIOLOGICAL-ACTIVITY [J].
FISHER, AG ;
COLLALTI, E ;
RATNER, L ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1985, 316 (6025) :262-265
[4]  
FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[5]  
2-J
[6]   IDENTIFICATION AND CHARACTERIZATION OF HIV-SPECIFIC RNASE-H BY MONOCLONAL-ANTIBODY [J].
HANSEN, J ;
SCHULZE, T ;
MELLERT, W ;
MOELLING, K .
EMBO JOURNAL, 1988, 7 (01) :239-243
[7]  
HANSEN J, 1987, J BIOL CHEM, V262, P12393
[8]   INFECTION OF HTLV-III/LAV IN HTLV-I-CARRYING CELLS MT-2 AND MT-4 AND APPLICATION IN A PLAQUE-ASSAY [J].
HARADA, S ;
KOYANAGI, Y ;
YAMAMOTO, N .
SCIENCE, 1985, 229 (4713) :563-566
[9]   EFFECTS OF SMALL INSERTIONS ON THE RNA-DEPENDENT DNA-POLYMERASE ACTIVITY OF HIV-1 REVERSE-TRANSCRIPTASE [J].
HIZI, A ;
BARBER, A ;
HUGHES, SH .
VIROLOGY, 1989, 170 (01) :326-329
[10]   EXPRESSION OF SOLUBLE, ENZYMATICALLY ACTIVE, HUMAN IMMUNODEFICIENCY VIRUS REVERSE-TRANSCRIPTASE IN ESCHERICHIA-COLI AND ANALYSIS OF MUTANTS [J].
HIZI, A ;
MCGILL, C ;
HUGHES, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (04) :1218-1222